<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In study NHL-BFM 90, we investigated whether the serum <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase (LDH) concentration and early response are useful markers for stratification of therapy for childhood B-cell <z:hpo ids='HP_0002664'>neoplasms</z:hpo> in addition to stage, if the outcome of patients with abdominal stage III and LDH &gt;/=500 U/L can be improved by high-dose (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX) at 5 g/m(2) instead of intermediate-dose (ID) MTX at 500 mg/m(2) in the preceding study 86; whether 2 therapy courses are enough for patients with complete resection; and whether combined systemic and intraventricular chemotherapy is efficacious for central <z:mp ids='MP_0008912'>nervous</z:mp> system-positive (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>(+)) patients </plain></SENT>
<SENT sid="1" pm="."><plain>After a cytoreductive prephase, treatment was stratified into 3 risk groups: patients in R1 (completely resected) received 2 5-day courses (ID-MTX, <z:chebi fb="0" ids="41879">dexamethasone</z:chebi>, oxazaphorins, <z:chebi fb="0" ids="4911">etoposide</z:chebi>, <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, and intrathecal therapy), patients in R2 (extra-abdominal primary only or <z:e sem="disease" ids="C0000735" disease_type="Neoplastic Process" abbrv="">abdominal tumor</z:e> and LDH &lt;500 U/L) received 4 courses containing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-MTX, and patients in R3 (abdominal primary and LDH &gt;/=500 U/L or bone marrow/<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>/multilocal <z:e sem="disease" ids="C0005940" disease_type="Disease or Syndrome" abbrv="">bone disease</z:e>) received 6 courses </plain></SENT>
<SENT sid="2" pm="."><plain>Incomplete responders after 2 courses received an intensification containing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-<z:chebi fb="0" ids="28680">cytarabine</z:chebi>/<z:chebi fb="0" ids="4911">etoposide</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with no or <z:e sem="disease" ids="C1300818" disease_type="Neoplastic Process" abbrv="">necrotic tumor</z:e> thereafter received 3 more courses; 6 patients with viable <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> received autologous bone marrow transplantation </plain></SENT>
<SENT sid="4" pm="."><plain>From April 1990 through March 1995, 413 evaluable patients were enrolled (R1, 17%; R2, 40%; and R3, 43%) </plain></SENT>
<SENT sid="5" pm="."><plain>The 6-year event-free survival (pEFS) was 89% +/- 2% for <z:hpo ids='HP_0000001'>all</z:hpo> and 100%, 96% +/-2%, and 78% +/- 3% in R1, R2, and R3, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>The pEFS of patients with abdominal stage III and LDH &gt;/=500 U/L was 81% +/- 4% as compared with 43% +/- 10% in study 86 </plain></SENT>
<SENT sid="7" pm="."><plain>Of 26 CNS(+) patients, 5 died early, but only 3 relapsed </plain></SENT>
</text></document>